Tvardi Therapeutics (LTS:0HTC) Buyback Yield %: -1.70 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HTC Tvardi Therapeutics Inc LTS:0HTC
18 GF Score
Price £3.38
! 1 Warning Sign
View Full Analysis

What is Tvardi Therapeutics Buyback Yield %?

Tvardi Therapeutics LTS:0HTC 18 Buyback Yield % is -1.70 as of Jul. 15, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Tvardi Therapeutics ranks better than 69.54% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Tvardi Therapeutics's current buyback yield was -1.70%.

Tvardi Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Buyback Yield % Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 -0.19 -0.15 -1.32 -1.77

LTS:0HTC vs HOWL, TPST, XCUR: Buyback Yield % Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Buyback Yield % falls into.


LTS:0HTC
18GF Score
Tvardi Therapeutics Inc LTS:0HTC
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tvardi Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Tvardi Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.397) / 0
=N/A%

Tvardi Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0.39) / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -1.70 mean?
Tvardi Therapeutics (LTS:0HTC) has a Buyback Yield % of -1.70 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #226 out of 742 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Tvardi Therapeutics' Buyback Yield % too high?
Tvardi Therapeutics' current Buyback Yield % is -1.70. Based on the distribution chart, Tvardi Therapeutics ranks #226 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tvardi Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Buyback Yield % compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #226 out of 742 companies for Buyback Yield %. This puts Tvardi Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Buyback Yield % is -1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Buyback Yield % of -1.70. The current Buyback Yield % is -1.70. Tvardi Therapeutics' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Buyback Yield % is -1.70 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
18GF Score

Get the complete analysis for LTS:0HTC

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£3.38
Price